modelDesmopressin
Extends from Pharmacolibrary.Drugs.ATC.H.H01BA02.
Information
| name: | Desmopressin | |
| ATC code: | H01BA02 | route: | intranasal |
| compartments: | 1 | |
| dosage: | 0.3 | mg |
| volume of distribution: | 48.3 | L |
| clearance: | 7.6 | L/h |
| other parameters in model implementation | ||
Desmopressin is a synthetic analogue of the natural pituitary hormone vasopressin. It is primarily used in the treatment of diabetes insipidus, nocturnal enuresis, and certain bleeding disorders such as hemophilia A and von Willebrand's disease. The drug is approved and widely used today.
Pharmacokinetics
Pharmacokinetic parameters reported in healthy adult volunteers after intranasal administration.
References
Sharthkumar, A, et al., & Shapiro, A (2008). Biologic response to subcutaneous and intranasal therapy with desmopressin in a large Amish kindred with Type 2M von Willebrand disease. Haemophilia : the official journal of the World Federation of Hemophilia 14(3) 539–548. DOI:10.1111/j.1365-2516.2008.01666.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/18312368
Schütte, LM, et al., & Mathôt, RAA (2018). Pharmacokinetic Modelling to Predict FVIII:C Response to Desmopressin and Its Reproducibility in Nonsevere Haemophilia A Patients. Thrombosis and haemostasis 118(4) 621–629. DOI:10.1160/TH17-06-0390 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29458233
Joukhadar, C, et al., & Eichler, HG (2003). A replicate study design for testing bioequivalence: a case study on two desmopressin nasal spray preparations. European journal of clinical pharmacology 59(8-9) 631–636. DOI:10.1007/s00228-003-0682-3 PUBMED:https://pubmed.ncbi.nlm.nih.gov/14564429
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)